Drug intelligence / Profile preview

(5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-difluorobenzyl)oxy]ethyl}-17-hydroxy-10-methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule with the molecular formula C27H36F2O3 and a molecular weight of approximately 446.6 g/mol[1][2][3]. It features a steroidal cyclopenta[a]phenanthrene core structure substituted with a 3',5'-difluorobenzyl ether side chain and hydroxyl/methyl groups at key positions[1][2]. The compound is listed in chemical databases as an experimental or research molecule; there is no evidence it has been approved for clinical use or assigned to any marketed drug product[3]. Its mechanism of action and pharmacological profile are not described in public sources; however—based on its structure—it may be related to steroid hormone analogs or modulators.

Other names
(1S,2S,7S,10R,11S,14S,15R)-15-(2-((3,5-difluorophenyl)methoxy)ethyl)-14-hydroxy-2-methyltetracyclo(8.7.0.02,.011,.1?)heptadecan-5-one(1S,2S,7S,10R,11S,14S,15R)-15-{2-[(3,5-difluorophenyl)methoxy]ethyl}-14-hydroxy-2-methyltetracyclo[8.7.0.02,.011,.1?]heptadecan-5-one
02

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-difluorobenzyl)oxy]ethyl}-17-hydroxy-10-methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-difluorobenzyl)oxy]ethyl}-17-hydroxy-10-methylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call